Intellia Thera CS (NTLA)

May 12, 2025, 9:07 AM EDT - 1 day ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 8, 2025, 11:37 AM EDT - 5 days ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 7 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 5, 2025, 4:44 AM EDT - 9 days ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

May 1, 2025, 7:30 AM EDT - 12 days ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 23, 2025, 9:50 AM EDT - 20 days ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 4 weeks ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 10, 2025, 10:40 AM EDT - 4 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 4 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 3, 2025, 1:03 PM EDT - 5 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 7:30 AM EDT - 5 weeks ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Mar 28, 2025, 6:24 AM EDT - 6 weeks ago

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Mar 26, 2025, 7:30 AM EDT - 6 weeks ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Mar 11, 2025, 5:43 PM EDT - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 6:03 PM EDT - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

Mar 6, 2025, 5:45 AM EST - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Mar 2, 2025, 9:30 AM EST - 2 months ago

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Feb 27, 2025, 12:30 PM EST - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:30 AM EST - 2 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Feb 26, 2025, 8:56 PM EST - 2 months ago

Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Feb 26, 2025, 1:31 PM EST - 2 months ago

Shareholders of Intellia Therapeutics, Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – NTLA

Feb 20, 2025, 5:39 PM EST - 2 months ago

NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information

Feb 20, 2025, 7:30 AM EST - 2 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Feb 13, 2025, 12:29 PM EST - 3 months ago

Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights